Fulltext

Evaluation of the Safety and Immunogenicity of the RTS,S/AS01E Malaria Candidate Vaccine When Integrated in the Expanded Program of Immunization

Agnandji, Selidji T. ; Asante, Kwaku Poku ; Lyimo, John ; Vekemans, Johan ; Soulanoudjingar, Solange S. ; Owusu, Ruth ; Shomari, Mwanajaa ; Leach, Amanda ; Fernandes, Jose ; Dosoo, David ; Chikawe, Maria ; Issifou, Saadou ; Osei-Kwakye, Kingsley ; Lievens, Marc ; Paricek, Maria ; Apanga, Stephen ; Mwangoka, Grace ; Okissi, Blaise ; Kwara, Evans ; Minja, Rose ; Lange, Jorn ; Boahen, Owusu ; Kayan, Kingsley ; Adjei, George ; Chandramohan, Daniel ; Jongert, Erik ; Demoitié, Marie-Ange ; Dubois, Marie-Claude ; Carter, Terrel ; Vansadia, Preeti ; Villafana, Tonya ; Sillman, Marla ; Savarese, Barbara ; Lapierre, Didier ; Ripley Ballou, William ; Greenwood, Brian ; Tanner, Marcel ; Cohen, Joe ; Kremsner, Peter G. ; Lell, Bertrand ; Owusu-Agyei, Seth ; Abdulla, Salim

In: The Journal of Infectious Diseases, 2010, vol. 202, no. 7, p. 1076-1087

Ajouter à la liste personnelle
    Titre
    • Evaluation of the Safety and Immunogenicity of the RTS,S/AS01E Malaria Candidate Vaccine When Integrated in the Expanded Program of Immunization
    Auteur
    • Agnandji, Selidji T.. Albert Schweitzer Hospital, Medical Research Unit Lambaréne, Lambaréné, Gabon
    • Asante, Kwaku Poku. Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana
    • Lyimo, John. Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo District Hospital, Bagamoyo, Tanzania
    • Vekemans, Johan. GlaxoSmithKline Biologicals, Rixensart, Belgium
    • Soulanoudjingar, Solange S.. Albert Schweitzer Hospital, Medical Research Unit Lambaréne, Lambaréné, Gabon
    • Owusu, Ruth. Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana
    • Shomari, Mwanajaa. Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo District Hospital, Bagamoyo, Tanzania
    • Leach, Amanda. GlaxoSmithKline Biologicals, Rixensart, Belgium
    • Fernandes, Jose. Albert Schweitzer Hospital, Medical Research Unit Lambaréne, Lambaréné, Gabon
    • Dosoo, David. Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana
    • Chikawe, Maria. Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo District Hospital, Bagamoyo, Tanzania
    • Issifou, Saadou. Albert Schweitzer Hospital, Medical Research Unit Lambaréne, Lambaréné, Gabon
    • Osei-Kwakye, Kingsley. Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana
    • Lievens, Marc. GlaxoSmithKline Biologicals, Rixensart, Belgium
    • Paricek, Maria. Albert Schweitzer Hospital, Medical Research Unit Lambaréne, Lambaréné, Gabon
    • Apanga, Stephen. Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana
    • Mwangoka, Grace. Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo District Hospital, Bagamoyo, Tanzania
    • Okissi, Blaise. Albert Schweitzer Hospital, Medical Research Unit Lambaréne, Lambaréné, Gabon
    • Kwara, Evans. Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana
    • Minja, Rose. Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo District Hospital, Bagamoyo, Tanzania
    • Lange, Jorn. Albert Schweitzer Hospital, Medical Research Unit Lambaréne, Lambaréné, Gabon
    • Boahen, Owusu. Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana
    • Kayan, Kingsley. Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana
    • Adjei, George. Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana
    • Chandramohan, Daniel. Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana
    • Jongert, Erik. GlaxoSmithKline Biologicals, Rixensart, Belgium
    • Demoitié, Marie-Ange. GlaxoSmithKline Biologicals, Rixensart, Belgium
    • Dubois, Marie-Claude. GlaxoSmithKline Biologicals, Rixensart, Belgium
    • Carter, Terrel. Program for Appropriate Technology in Health Malaria Vaccine Initiative, Bethesda, Maryland
    • Vansadia, Preeti. Program for Appropriate Technology in Health Malaria Vaccine Initiative, Bethesda, Maryland
    • Villafana, Tonya. Program for Appropriate Technology in Health Malaria Vaccine Initiative, Bethesda, Maryland
    • Sillman, Marla. Program for Appropriate Technology in Health Malaria Vaccine Initiative, Bethesda, Maryland
    • Savarese, Barbara. Program for Appropriate Technology in Health Malaria Vaccine Initiative, Bethesda, Maryland
    • Lapierre, Didier. GlaxoSmithKline Biologicals, Rixensart, Belgium
    • Ripley Ballou, William. GlaxoSmithKline Biologicals, Rixensart, Belgium
    • Greenwood, Brian. Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana
    • Tanner, Marcel. Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo District Hospital, Bagamoyo, Tanzania
    • Cohen, Joe. GlaxoSmithKline Biologicals, Rixensart, Belgium
    • Kremsner, Peter G.. Albert Schweitzer Hospital, Medical Research Unit Lambaréne, Lambaréné, Gabon
    • Lell, Bertrand. Albert Schweitzer Hospital, Medical Research Unit Lambaréne, Lambaréné, Gabon
    • Owusu-Agyei, Seth. Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana
    • Abdulla, Salim. Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo District Hospital, Bagamoyo, Tanzania
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • The Journal of Infectious Diseases, 2010, vol. 202, no. 7, p. 1076-1087. The University of Chicago Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:291914
    Summary
    Background. The RTS,S/AS01E malaria candidate vaccine is being developed for immunization of African infants through the Expanded Program of Immunization (EPI). Methods. This phase 2, randomized, open, controlled trial conducted in Ghana, Tanzania, and Gabon evaluated the safety and immunogenicity of RTS,S/AS01E when coadministered with EPI vaccines. Five hundred eleven infants were randomized to receive RTS,S/AS01E at 0, 1, and 2 months (in 3 doses with diphtheria, tetanus, and wholecell pertussis conjugate [DTPw]; hepatitis B [HepB]; Haemophilus influenzae type b [Hib]; and oral polio vaccine [OPV]), RTS,S/AS01E at 0, 1, and 7 months (2 doses with DTPwHepB/Hib+OPV and 1 dose with measles and yellow fever), or EPI vaccines only. Results. The occurrences of serious adverse events were balanced across groups; none were vaccine-related. One child from the control group died. Mild to moderate fever and diaper dermatitis occurred more frequently in the RTS,S/AS01E coadministration groups. RTS,S/AS01E generated high anti-circumsporozoite protein and anti- hepatitis B surface antigen antibody levels. Regarding EPI vaccine responses upon coadministration when considering both immunization schedules, despite a tendency toward lower geometric mean titers to some EPI antigens, predefined noninferiority criteria were met for all EPI antigens except for polio 3 when EPI vaccines were given with RTS,S/AS01E at 0, 1, and 2 months. However, when antibody levels at screening were taken into account, the rates of response to polio 3 antigens were comparable between groups. Conclusion. RTS,S/AS01E integrated in the EPI showed a favorable safety and immunogenicity evaluation. Trial registration. ClinicalTrials.gov identifier: NCT00436007. GlaxoSmithKline study ID number: 106369 (Malaria-050)